Webinar on-demand: Busting the myths of decentralized trials
The truth about depot-to-patient shipments
Duration: 60 mins
- Andrea Zobel, PhD, Senior Director, Personalized Supply Chain, World Courier
- Lisa Falzone, Principal Clinical Supply Manager, Bayer
- Alexander Pytlarz, PharmD, President of Operations, Infuserve America
- Mark Saxon, PA-C, MBA, Senior Vice President, Operations Clinical trials, Matrix Medical Network
The decentralized trials approach isn’t a new concept. It allows patients to receive most – if not all – of their treatment at home rather than at a clinical site. Many are the benefits of this patient-centric model. However, although more than 75% of clinical trials professionals report that at least some of their activities have already been decentralized due to the COVID-19 outbreak, many still hesitate to switch, raising concerns about regulations, IMP integrity, data protection and patient care.
On December 14th, 2021, Andrea Zobel, Senior Director Personalized Supply Chain at World Courier, delved into decentralized trials logistics and setting up a best-in-class central dispensing model ensuring compliance, integrity, end-to-end visibility, and safety.
She was joined by industry experts from the International Society for Pharmaceutical Engineering (ISPE)’s Direct-to-Patient task force for a live Q&A where they discussed the most common concerns and myths raised around the central dispensing model.
- Understand the decentralized trials approach and the central dispensing model
- Clarify any doubts and misconceptions about the efficiency and compliance of decentralized trials
- Hear about successful case studies from industry experts
- Ask questions live to decentralized trials experts
* Source: Decentralized Clinical Trials in 2020: A Global Survey, PharmaIntelligence Informa